Integra LifeSciences reports Q1 adjusted EPS 55c, consensus 55c

Reports Q1 revenue $368.9M, consensus $361.96M. “We are pleased with our strong first quarter financial performance, which reflects the strength of our diversified portfolio and the unwavering commitment of our colleagues worldwide to our customers and patients,” said CEO Jan De Witte. “As we look to the rest of the year, we remain focused on executing our key priorities, particularly on enhancing quality, reliability and resilience of our manufacturing operations and supply chain, advancing our new product pipeline, and integrating the Acclarent business and welcoming our new colleagues.”